Akari Therapeutics

Akari Therapeutics

Akari Therapeutics is a clinical-stage biotechnology company incorporated in the United Kingdom with American depositary shares trading on the Nasdaq. The firm advanced a C5 complement inhibitor, nomacopan, as its core asset, initially targeting paroxysmal nocturnal hemoglobinuria before pivoting toward pediatric thrombotic microangiopathy associated with hematopoietic stem-cell transplant—a rare condition with no approved therapies. The company has historically maintained a lean operating model, outsourcing much of its manufacturing and clinical operations while concentrating internal resources on regulatory strategy and trial design. Nomacopan operates as both a C5 complement inhibitor and a leukotriene B4 antagonist, a dual mechanism Akari believes differentiates it from pure-play complement drugs. The current strategy centers on enrollment and data from a single pivotal Phase 3 pediatric trial. The firm has explored other indications including bullous pemphigoid and atopic keratoconjunctivitis, but publicly disclosed priorities have tightened around the pediatric HSCT-TMA program. In late 2022, Akari announced a merger with Peak Bio, which brought additional pipeline assets and a public listing vehicle; the combined entity trades under the Akari name. Akari does not disclose a large internal research workforce or extensive laboratory infrastructure. The firm's historical regulatory filings describe a controlled burn-rate strategy, relying on periodic public-market financings and partnership discussions to fund operations. The merger with Peak Bio in November 2023 extended cash runway and introduced co-development interests. Akari's board has historically included cross-border biotechnology and rare-disease veterans who bring expertise in navigating European and U.S. regulatory pathways for orphan-designated products. Unlike discovery-stage biotechs that maintain broad-platform science, Akari is structured around a single pivotal clinical outcome. The company's value proposition is binary—regulatory approval for nomacopan's lead indication or strategic sale of the asset—mirroring a model common among European public biotechs with no internal commercial infrastructure. Governance includes a board-level focus on capital allocation toward the Phase 3 readout expected in the 2025–2026 window.